Would you like to take some more ruxolitinib after your fedratinib?
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19695 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Jean-Christophe Ianotto. Beteiligte Einrichtung: Department of Haematology, Institute of Oncology and Haematology, University Hospital of Brest, Brest, France. Hauptthemen laut MEDLINE: Nitriles, Pyrazoles, Pyrimidines, Primary Myelofibrosis. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In Europe, ruxolitinib and fedratinib are the only JAK2 inhibitors available in local pharmacies. According to trial data, myelofibrosis patients should mostly receive ruxolitinib as first‐line treatment and fedratinib in case of failure or intolerance (depending on their profile). Is it possible to reverse the choice of these drugs? Commentary on: Palandri et al. Ruxolitinib after Fedratinib failure in patients with myelofibrosis: a real‐world case series. Br J Haematol 2024; 205:1605‐1609.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology, Institute of Oncology and Haematology, University Hospital of Brest, Brest, France.
ORCID-Profile: Jean-Christophe Ianotto
Zitieren
APA
Ianotto, J. C. (2024). Would you like to take some more ruxolitinib after your fedratinib?. British Journal of Haematology. https://doi.org/10.1111/bjh.19695
Vancouver
Ianotto JC. Would you like to take some more ruxolitinib after your fedratinib?. British Journal of Haematology. 2024. doi:10.1111/bjh.19695
BibTeX
@article{Ianotto2024,
author = {Ianotto, Jean-Christophe},
title = {Would you like to take some more ruxolitinib after your fedratinib?},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19695}
}
EUVIMED